Review
Neurosciences
Ashish Patel, Arya Patel, Darshini Patel, Krina Patel, Tushar Bambharoliya
Summary: Cariprazine is a novel atypical antipsychotic drug that was approved by the USFDA in 2015 for the treatment of schizophrenia and bipolar manic or mixed episodes in adults. It differs pharmacologically from other antipsychotic drugs due to its partial agonist action on dopamine and serotonin receptors. It also has a unique pharmacokinetic profile due to the formation of two significant metabolites. This review study demonstrates the effectiveness and safety of cariprazine in bipolar I disorder and schizophrenia, highlighting its potential as a promising therapeutic alternative.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
(2023)
Review
Psychiatry
Borjanka Batinic, Ivan Ristic, Milica Zugic, David S. Baldwin
Summary: Cariprazine is a medication approved for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, showing efficacy across a wide array of symptoms and a favorable side effect profile. It may be a drug of choice for patients with predominant negative and cognitive symptoms of schizophrenia. Its longer half-life and delayed time to relapse in patients with schizophrenia compared to other antipsychotics suggest potential advantages in clinical practice.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Clinical Neurology
Camilla Gesi, Silvia Paletta, Maria Carlotta Palazzo, Bernardo Dell'Osso, Claudio Mencacci, Giancarlo Cerveri
Summary: Cariprazine is an antipsychotic medication approved for the treatment of schizophrenia, with a preference for dopamine D-3 receptors and also partial agonism at 5-HT1A receptors for an antidepressant effect. Common adverse events include extrapyramidal symptoms and akathisia. In addition to schizophrenia, cariprazine is also approved for the treatment of bipolar I disorder.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)
Review
Clinical Neurology
Beatriz Corte-Real, Rodrigo Saraiva, Catarina Rodrigues Cordeiro, Benicio N. Frey, Flavio Kapczinski, Taiane de Azevedo Cardoso
Summary: The study aimed to investigate whether atypical antipsychotics (AA) can induce mania in mood disorders. A systematic review and meta-analysis showed that AA-induced mania is rare and the use of AA is more effective in preventing the development of mania compared to placebo.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Psychiatry
Andre Do, Kamyar Keramatian, Ayal Schaffer, Lakshmi Yatham
Summary: Bipolar disorder is a chronic psychiatric disorder with significant impairment in psychosocial functioning. While current pharmacological treatments have limitations, cariprazine appears to be an effective and well-tolerated option for both manic and depressive episodes of BD.
FRONTIERS IN PSYCHIATRY
(2021)
Review
Chemistry, Medicinal
Mauricio Tohen
Summary: Depressive episodes are common in bipolar disorder and often lead to poor functional outcomes. Limited treatments are approved for bipolar depression, but recent approval of cariprazine, a dopamine antagonist/partial agonist, shows it to be effective and well-tolerated.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Psychiatry
Leonid Braverman, Camil Fuchs, Abraham Weizman, Michael Poyurovsky
Summary: Evidence suggests a higher comorbidity rate of obsessive-compulsive disorder (OCD) in bipolar disorder (BD) patients, particularly in those experiencing bipolar depression (BP-D). A study found 26% of BD patients with their first depressive episode also had OCD, while 23.2% met criteria for subthreshold OCD. No differences in demographic and clinical variables were observed between BD patients with and without OCD. Further research is needed to explore the longitudinal course, treatment approaches, and outcomes of comorbid BP-D/OCD.
PSYCHIATRY RESEARCH
(2021)
Article
Clinical Neurology
Qin Tang, Qian Cui, Yuyan Chen, Jiaxin Deng, Wei Sheng, Yang Yang, Fengmei Lu, Yuhong Zeng, Kexing Jiang, Huafu Chen
Summary: Using the DRePS method, common and specific alterations in local functional connectivity patterns were found in patients with BDD and MDD. Patients with both disorders showed decreased DRePS values in multiple brain regions, with MDD patients exhibiting specific decreases in the left caudate. Voxel signals in these regions also contributed to the classification of the two diagnoses.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Clinical Neurology
Qin Tang, Qian Cui, Yuyan Chen, Jiaxin Deng, Wei Sheng, Yang Yang, Fengmei Lu, Yuhong Zeng, Kexing Jiang, Huafu Chen
Summary: This study characterized the common and specific alterations in the dynamic local functional connectivity pattern in patients with bipolar depressive disorder (BDD) and major depressive disorder (MDD) using a newly developed method called dynamic regional phase synchrony (DRePS). The findings provided new insight into the neural mechanism of BDD and MDD patients and could potentially inform the diagnosis and treatment of these disorders.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Clinical Neurology
Wen Liu, Xiaowei Jiang, Yide Xin, Zijing Deng, Yu Xie, Yifang Zhou, Yifan Wu, Qikun Sun, Lingtao Kong, Feng Wu, Yanqing Tang
Summary: This study identified differences in dynamic amplitude low-frequency fluctuations (dALFF) between patients with major depressive disorder (MDD) and those who converted to bipolar disorder (BD), and described the role of sex effects in differentiating the two disorders. A positive correlation was found between dALFF values and WCST scores in MDD patients, and this correlation was observed only in female MDD patients in the occipital gyrus.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Psychiatry
Joseigla Pinto de Oliveira, Karen Jansen, Taiane de Azevedo Cardoso, Thaise Campos Mondin, Luciano Dias de Mattos Souza, Ricardo Azevedo da Silva, Fernanda Pedrotti Moreira
Summary: The study aimed to assess the role of childhood trauma in differentiating MDD and BD, as well as to describe the conversion rate from MDD to BD and its predictors. Findings indicated that predictors of conversion to BD included lower education, substance abuse, younger age of onset, and family history, while childhood trauma was not a significant risk factor for conversion.
PSYCHIATRY RESEARCH
(2021)
Article
Clinical Neurology
Alessandro Miola, Leonardo Tondo, Marco Pinna, Martina Contu, Ross J. Baldessarini
Summary: The study compared patients diagnosed with DSM-5 type II bipolar disorder (BD2) and major depressive disorder (MDD). The results showed significant differences between BD2 and MDD patients in terms of symptoms, morbidity, and treatment, which can contribute to better differentiation and treatment planning for the two disorders.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Biochemistry & Molecular Biology
Qingxia Yang, Qiaowen Xing, Qingfang Yang, Yaguo Gong
Summary: Schizophrenia, bipolar disorder, and major depressive disorder are the most common psychiatric disorders. Diagnosing these disorders is difficult due to overlaps in genetic epidemiology and molecular genetics. This study used transcriptomic data to identify key genes and construct a classification model for differentiating these disorders. The model showed potential for improving the diagnoses of these psychiatric disorders.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2022)
Article
Clinical Neurology
Maya Kuperberg, Douglas Katz, Sophie L. A. Greenebaum, Nevita George, Louisa G. Sylvia, Gustavo Kinrys, Astrid Desrosiers, Andrew A. Nierenberg
Summary: This study examined the relationship between psychotic symptoms during bipolar depressive episodes and suicidal ideation among outpatients with bipolar disorder. The results indicated that patients with psychotic symptoms were more likely to report active suicidal thoughts, including specific plans and methods.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Psychiatry
Hyeyoung Kim, Sang Jin Rhee, Hyunju Lee, Dohyun Han, Tae Young Lee, Minah Kim, Eun Young Kim, Jun Soo Kwon, Hyunsuk Shin, Hyeyoon Kim, Yong Min Ahn, Kyooseob Ha
Summary: High-throughput proteomic technologies were used to identify dysregulated proteins in the plasma of patients with major depressive disorder (MDD) and bipolar disorder (BD). Several proteins were found to be altered in both disorders, with higher fold changes observed in MDD patients. These findings may aid in identifying candidate biomarkers for mood disorders.
PSYCHIATRY RESEARCH
(2021)
Article
Neurosciences
Stefania Chiappini, Franca Ceci, Alessio Mosca, Francesco Di Carlo, Julius Burkauskas, Mauro Pettorruso, Giovanni Martinotti, Amira Guirguis, John M. M. Corkery, Norbert Scherbaum, Fabrizio Schifano, Massimo Di Giannantonio
Summary: This study aimed to explore the consumption and misuse of over-the-counter (OTC) medicines in Italy and identify the characteristics of individuals involved in this phenomenon, as well as potential risk factors. It was found that OTC misuse was associated with knowledge of the effects of OTC, while educational level appeared to be a protective factor. Therefore, increased attention and preventive strategies are needed to address OTC misuse.
CURRENT NEUROPHARMACOLOGY
(2023)
Article
Psychiatry
Borwin Bandelow, Christer Allgulander, David S. Baldwin, Daniel Lucas da Conceicao Costa, Damiaan Denys, Nesrin Dilbaz, Katharina Domschke, Eric Hollander, Siegfried Kasper, Hans-Juergen Moeller, Elias Eriksson, Naomi A. Fineberg, Josef Haettenschwiler, Hisanobu Kaiya, Tatiana Karavaeva, Martin A. Katzman, Yong-Ku Kim, Takeshi Inoue, Leslie Lim, Vasilios Masdrakis, Jose M. Menchon, Euripedes C. Miguel, Antonio E. Nardi, Stefano Pallanti, Giampaolo Perna, Dan Rujescu, Vladan Starcevic, Dan J. Stein, Shih-Jen Tsai, Michael Van Ameringen, Anna Vasileva, Zhen Wang, Joseph Zohar
Summary: According to the guideline by the World Federation of Societies of Biological Psychiatry, OCD and PTSD can be effectively treated with medications and CBT. SSRIs and CBT are first-line treatments for OCD, while SSRIs and venlafaxine are first-line treatments for PTSD.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
(2023)
Article
Substance Abuse
Giovanni Martinotti, Giuseppe Manuel Festa, Franca Ceci, Ilenia Di Muzio, Antonino Callea, Ada Capparelli, Ludovica Bonifaci, Eleonora Chillemi, Maria Pepe, Mauro Pettorruso, Stefania Chiappini, Marco Di Nicola, Luigi Janiri
Summary: The present study aims to evaluate the psychometric properties of the CTQ-15, a revised version of CTQ with 15 items. The results show that CTQ-15 is reliable and practical for identifying the three dimensions of craving in clinical practice.
ALCOHOL AND ALCOHOLISM
(2023)
Review
Clinical Neurology
M. Fornaro, C. I. Cattaneo, D. De Berardis, F. V. Ressico, G. Martinotti, E. Vieta
Summary: There is limited evidence about antidepressant discontinuation syndrome (ADS) and related outcomes, but it may have a significant impact on some patients. Gradual tapering and integrative management should be considered to minimize adverse effects during the discontinuation process.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Letter
Clinical Neurology
Laura Orsolini, Giulio Longo, Silvia Bellagamba, Takahiro A. Kato, Umberto Volpe
PSYCHIATRY AND CLINICAL NEUROSCIENCES
(2023)
Review
Nutrition & Dietetics
Giuseppe Marano, Marianna Mazza, Francesco Maria Lisci, Michele Ciliberto, Gianandrea Traversi, Georgios Demetrios Kotzalidis, Domenico De Berardis, Lucrezia Laterza, Gabriele Sani, Antonio Gasbarrini, Eleonora Gaetani
Summary: There is increasing interest in the role of intestinal microbiota and autoimmune processes in psychiatric diseases. Altered communication between the microbiota-gut-brain axis may be a cause of psychiatric disorders. This review explores the evidence for the involvement of gut microbiota in psychiatric diseases and the impact of diet on microbiota and mental health. Changes in gut microbiota composition can lead to increased intestinal permeability, resulting in a cytokine storm, systemic inflammation, and immune response. These events can affect neurotransmitter release, alter the hypothalamic-pituitary-adrenal axis, and reduce trophic brain factors. Further research is needed to understand the underlying mechanisms connecting gut microbiota and psychiatric disorders.
Review
Neurosciences
Andrea Amerio, Eleonora Vai, Edoardo Bruno, Alessandra Costanza, Andrea Escelsior, Anna Odone, Domenico De Berardis, Andrea Aguglia, Gianluca Serafini, Mario Amore, Seyyed Nassir Ghaemi
Summary: Despite the pandemic triggering a wave of research, few studies have looked into the impact of COVID-19 on Italy's community-based mental health care system. This study aimed to summarize existing evidence and also drew from daily clinical practice. Despite reduced hospital care, community mental health centers promoted continuity of care through teleconsultation, leading to lower risk of deterioration and hospitalization for patients. This model received satisfaction from both patients and mental health workers.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
(2023)
Editorial Material
Psychiatry
Domenico De Berardis, Michele Fornaro, Claudia Carmassi
FRONTIERS IN PSYCHIATRY
(2023)
Article
Medicine, General & Internal
Najma Iqbal Malik, Sidra Saleem, Irfan Ullah, Syeda Tayyaba Rehan, Domenico De Berardis, Mohsin Atta
Summary: The present study aimed to investigate the impact of psychosocial factors on the stigma of mental illness among relapsed drug addicts in Punjab, Pakistan. A sample of 116 relapsed drug addicts was collected using purposive sampling technique, and self-report measures were used to assess the variables of interest. The results revealed that self-efficacy, social support, conscientiousness were negative predictors, while neuroticism was a positive predictor of stigma. Moreover, social support was found to moderate the relationship between self-efficacy and stigma, and self-efficacy moderated the relationship between social support and stigma. These findings highlight the significant role of psychosocial factors in addiction relapse.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Psychiatry
Delfina Janiri, Gaia Sampogna, Umberto Albert, Filippo Caraci, Giovanni Martinotti, Gianluca Serafini, Alfonso Tortorella, Alessandro Zuddas, Andrea Fiorillo, Gabriele Sani
Summary: This study conducted an umbrella review to analyze the efficacy and safety of lithium in mood disorders across different age groups and special clinical conditions. The results showed that lithium may be effective in treating pediatric bipolar disorders and preventing mood episodes during the peripartum period. In addition, it may also be beneficial for elderly individuals with bipolar disorders and treatment-resistant major depressive disorder (MDD).
INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS
(2023)
Review
Health Care Sciences & Services
Giacomo d'Andrea, Gianluca Mancusi, Maria Chiara Santovito, Carlotta Marrangone, Fabrizio Martino, Mario Santorelli, Andrea Miuli, Francesco Di Carlo, Maria Salvina Signorelli, Massimo Clerici, Mauro Pettorruso, Giovanni Martinotti
Summary: A systematic review found that repetitive transcranial magnetic stimulation (rTMS) has been approved as an effective intervention for treatment-resistant depression (TRD). Most studies suggest that maintenance protocols can reduce the risk of relapse, but there is heterogeneity in these protocols. Administering two or fewer stimulations per month is ineffective in sustaining the antidepressant effect or reducing relapse risk. The risk of relapse is most pronounced after five months from acute treatment. Maintenance TMS is a resourceful strategy that can significantly reduce relapse risk and should be considered for future use.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Health Care Sciences & Services
Laura Orsolini, Simone Pompili, Antonella Mauro, Umberto Volpe
Summary: This study investigated predictors associated with perinatal depression (PND) in pregnant and puerperal women in Italy during the COVID-19 pandemic. The results showed that being a foreigner, having a positive family psychiatric history, pre-pregnancy medical comorbidity, and comorbid medical illness during pregnancy were significantly associated with PND. The findings highlight the importance of screening all fertile women, particularly in gynecological and medical settings, to identify at-risk women for PND and provide timely psychiatric consultation.
Article
Neurosciences
Elham Lalegani, Negin Eissazade, Mohammadreza Shalbafan, Razieh Salehian, Seyed Vahid Shariat, Sanaz Askari, Laura Orsolini, Shiva Soraya
Summary: Drug holidays may be a safe and effective strategy for managing SSRI-induced sexual dysfunction in women, alongside improving mental health.
Article
Chemistry, Medicinal
Stefania Chiappini, Rachel Vickers-Smith, Daniel Harris, G. Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Giovanni Martinotti, Stefano L. Sensi, Fabrizio Schifano
Summary: Media reports have raised concerns about the misuse of antidiabetic drugs as weight-loss treatments in non-obese individuals. This study examined the pharmacovigilance signals of semaglutide, a GLP-1 analogue, compared to other GLP-1 receptor agonists and the phentermine-topiramate combination. The analysis of adverse event reports from the FDA's FAERS database revealed a higher risk of misuse associated with semaglutide.
Article
Psychiatry
Giovanni Ostuzzi, Federico Tedeschi, Federico Bertolini, Carlo Cotugno, Andrea Aguglia, Francesco Bartoli, Giuseppe Carra, Armando D'Agostino, Giovanni Martinotti, Corrado Barbui, Chiara Gastaldon, Davide Papola
Summary: This study examines the effects of long-acting antipsychotics (LAIs) in unselected populations with severe mental illness. The findings suggest that LAIs might be beneficial in such populations, provided that adherence is maintained. LAI continuers spent less time hospitalized, but received more antipsychotics and suffered from more cumulative adverse events over time.
